Is the Moderna stock a bargain ahead of FDA decision?

The American biotechnology giant Moderna (NASDAQ: MRNA) stock hit a fresh 52-week low of $115.61 on Monday ahead of the FDA advisory committee meeting to decide whether to give approval to Moderna’s COVID-19 vaccine for young children.

Moderna was the first drugmaker with an experimental COVID-19 vaccine to begin clinical testing in humans in the U.S. Moderna’s vaccine is currently available only to people 18 and older.

Read more here -